glp-1 receptor agonist transdermal patch Scientists rethink delivery to improve dosing, tolerability, and adherence Peptide GLP-1 receptor agonists: From

Yue and colleagues showed that the GLP-1 agonist, liraglutide, reduced the transcriptional factor KLF2 and the rescued ox-LDL induced reduction of mitogen-activated protein kinase (MAPK) kinase extracellular signal regulated kinase 5 (ERK5) phosphorylation, and blockage of ERK5 activity on KLF2 expression [60]

Eli Lilly is due to submit orforglipron for Type 2 diabetes to the FDA later this year

Emerging data also point to benefits in conditions such as obstructive sleep apnea (OSA) and chronic kidney disease, including tirzepatide for moderate-to-severe OSA in adults with obesity and semaglutide for reducing kidney and cardiovascular risk in adults with CKD and T2D

Patients seeking GLP-1 therapy should rely on FDA-approved medications with established efficacy profiles, including landmark trials like STEP (semaglutide) demonstrating approximately 15% body weight reduction and SCALE (liraglutide) showing 5-8% weight reduction, along with improved glycemic control in patients with diabetes

I dont think so, but yeah, I do think that the elephant in the room here is how do you, how do you sustain this in, in a way that people dont just fall off a cliff once they come off it

It sounds like some Tricare for Life members are in the same boat